These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3252078)

  • 41. Susceptibility of 89,517 gram-negative isolates to aztreonam and other antibiotics.
    Lindsay G; Woods P
    Chemioterapia; 1987 Jun; 6(2 Suppl):106. PubMed ID: 3509363
    [No Abstract]   [Full Text] [Related]  

  • 42. Gram-negative bacillary pneumonia in the nosocomial setting. Role of aztreonam therapy.
    Cook JL
    Am J Med; 1990 Mar; 88(3C):34S-37S; discussion 38S-42S. PubMed ID: 2316557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative in vitro antimicrobial activity of carumonam (Ro 17-2301) and its influence on the activity of other antibiotics.
    Hoepelman IM; Steyger G; Rozenberg-Arska M; Verhoef J
    Chemotherapy; 1987; 33(2):103-9. PubMed ID: 3568798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Isolated bacteria and susceptibilities to antimicrobial agents in biliary infections.
    Mukaiya M; Hirata K; Katsuramaki T; Kihara C; Kimura Y; Yamaguchi K; Furuhata T; Hata F
    Hepatogastroenterology; 2005; 52(63):686-90. PubMed ID: 15966183
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aztreonam: the first monobactam antibiotic.
    Stutman HR
    Pediatr Infect Dis J; 1987 Jun; 6(6):550-5. PubMed ID: 3302907
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment with aztreonam of gram negative infections in patients seropositive for HIV].
    Catania S; Mascellino MT; Trinchieri V; Musso R; Lorenzi A; Cirelli A
    Riv Eur Sci Med Farmacol; 1988 Aug; 10(4):317-21. PubMed ID: 3274906
    [No Abstract]   [Full Text] [Related]  

  • 47. [Evaluation of the in vitro activity of aztreonam on 1990 gram-negative bacterial strains recently isolated in Campania hospitals].
    Covelli I; Bolletti-Censi M; Fortunato A; Guarino A; Spagnoletti G; Amato G; Nani E; Anzivino D; Lavitola A; Gulletta E
    Boll Ist Sieroter Milan; 1986; 65(1):22-31. PubMed ID: 3521671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [In vitro chemo-antibiotic sensitivity of gram-negative bacteria from various biological materials. Comparison between aztreonam and other agents].
    Monaci E; Monaci R; Giacalone G; Meoni S
    Minerva Med; 1987 May; 78(9):617-22. PubMed ID: 3587729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The newer cephalosporins. Aztreonam and imipenem.
    Ennis DM; Cobbs CG
    Infect Dis Clin North Am; 1995 Sep; 9(3):687-713. PubMed ID: 7490439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Rifampicin: laboratory study on Gram negative bacteria and Staphylococcus aureus].
    Silva J; Zemelman R; Angélica Mondaca M
    Rev Latinoam Microbiol; 1978; 20(2):69-73. PubMed ID: 288114
    [No Abstract]   [Full Text] [Related]  

  • 51. Aztreonam versus gentamicin, each with clindamycin, in the treatment of endometritis.
    Gibbs RS; Blanco JD; Lipscomb KA; St Clair PJ
    Obstet Gynecol; 1985 Jun; 65(6):825-9. PubMed ID: 3889748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro study of the sensitivity of 1030 hospital-isolated bacterial strains to aztreonam.
    Grassi L
    Chemioterapia; 1984 Aug; 3(4):262-6. PubMed ID: 6543433
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Susceptibility of Pseudomonas aeruginosa to aztreonam in comparison to other pseudomonas-active beta-lactam antibiotics and gentamicin].
    Wundt W; Lange KP; Baumgärtner M
    Arzneimittelforschung; 1985; 35(8):1322-5. PubMed ID: 3935123
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Sensitivity of nonfermenting gram-negative bacteria of clinical origin to antibacterial preparations].
    Shchenderov BA; Serkova GP; Tiurin MV
    Antibiotiki; 1984 Mar; 29(3):191-5. PubMed ID: 6732205
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
    Stefani S; Bonfiglio G; Bianchi C; Zollo A; Nicoletti G
    Drugs Exp Clin Res; 1998; 24(2):105-13. PubMed ID: 9675551
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aztreonam activity, pharmacology, and clinical uses.
    Neu HC
    Am J Med; 1990 Mar; 88(3C):2S-6S; discussion 38S-42S. PubMed ID: 2180293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro susceptibility of hospital isolates of various bacterial genera to chlorhexidine.
    Pitt TL; Gaston MA; Hoffman PN
    J Hosp Infect; 1983 Jun; 4(2):173-6. PubMed ID: 6195226
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical studies of aztreonam in Japan.
    Hara K; Kobayashi H; Nishiura T; Yura J; Saito A
    Rev Infect Dis; 1985; 7 Suppl 4():S810-24. PubMed ID: 3909341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imipenem and aztreonam: current role in antimicrobial therapy.
    Rice LB; Eliopoulos GM
    Curr Clin Top Infect Dis; 1989; 10():109-39. PubMed ID: 2679691
    [No Abstract]   [Full Text] [Related]  

  • 60. Modulation of the intestinal flora of mice by treatment with aztreonam and tigemonam.
    van Ogtrop ML; Guiot HF; Mattie H; van Strijen E; Sekh BR; van Furth R
    Antimicrob Agents Chemother; 1991 May; 35(5):983-5. PubMed ID: 1854181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.